Jade Biosciences (JBIO) Stock Forecast & Price Target

Compare

144 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JBIO Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Jade

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JBIO Stock 12 Month Forecast

Average Price Target

$17.00

▲(146.73%Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Jade Biosciences in the last 3 months. The average price target is $17.00 with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 146.73% change from the last price of $6.89.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","32":"$32","59":"$59","86":"$86","113":"$113"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,32,59,86,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Mar<br/>2024","9":"Jun<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10,10.538461538461538,11.076923076923077,11.615384615384615,12.153846153846153,12.692307692307692,13.23076923076923,13.76923076923077,14.307692307692307,14.846153846153847,15.384615384615383,15.923076923076923,16.46153846153846,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10,10.538461538461538,11.076923076923077,11.615384615384615,12.153846153846153,12.692307692307692,13.23076923076923,13.76923076923077,14.307692307692307,14.846153846153847,15.384615384615383,15.923076923076923,16.46153846153846,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10,10.538461538461538,11.076923076923077,11.615384615384615,12.153846153846153,12.692307692307692,13.23076923076923,13.76923076923077,14.307692307692307,14.846153846153847,15.384615384615383,15.923076923076923,16.46153846153846,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.57,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.57,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.57,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.57,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.57,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.34,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.14,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.44,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$17.00

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura ChicoWedbush

Wedbush

$17

Buy

146.73%

Upside

Reiterated

05/15/25

Jade Biosciences (JBIO) Receives a Buy from Wedbush

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/14/25

Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership

Andreas ArgyridesOppenheimer

Oppenheimer

$105

Hold

1423.95%

Upside

Reiterated

08/13/24

Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (NASDAQ: ORIC), Aerovate Therapeutics (NASDAQ: AVTE) and McKesson (NYSE: MCK)

Liisa BaykoEvercore ISI

Evercore ISI

$70

Hold

915.97%

Upside

Downgraded

06/17/24

Aerovate Therapeutics (AVTE) was downgraded to a Hold Rating at Evercore ISI

Vamil DivanGuggenheim

Guggenheim

―

Hold

―

Downgraded

06/17/24

Aerovate Therapeutics downgraded to Neutral from Buy at Guggenheim

Julian HarrisonBTIG

BTIG

―

Hold

―

Downgraded

06/17/24

Aerovate Therapeutics downgraded to Neutral from Buy at BTIGAerovate Therapeutics downgraded to Neutral from Buy at BTIG

Tiago FauthWells Fargo

Wells Fargo

$70

Hold

915.97%

Upside

Downgraded

06/17/24

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alcon (NYSE: ALC), Aerovate Therapeutics (NASDAQ: AVTE) and Globus Medical (NYSE: GMED)

Dennis DingJefferies

Jefferies

$2,275→$70

Hold

915.97%

Upside

Downgraded

06/17/24

Aerovate Therapeutics downgraded to Hold from Buy at JefferiesAerovate Therapeutics downgraded to Hold from Buy at Jefferies

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura ChicoWedbush

Wedbush

$17

Buy

146.73%

Upside

Reiterated

05/15/25

Jade Biosciences (JBIO) Receives a Buy from Wedbush

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/14/25

Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership

Andreas ArgyridesOppenheimer

Oppenheimer

$105

Hold

1423.95%

Upside

Reiterated

08/13/24

Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (NASDAQ: ORIC), Aerovate Therapeutics (NASDAQ: AVTE) and McKesson (NYSE: MCK)

Liisa BaykoEvercore ISI

Evercore ISI

$70

Hold

915.97%

Upside

Downgraded

06/17/24

Aerovate Therapeutics (AVTE) was downgraded to a Hold Rating at Evercore ISI

Vamil DivanGuggenheim

Guggenheim

―

Hold

―

Downgraded

06/17/24

Aerovate Therapeutics downgraded to Neutral from Buy at Guggenheim

Julian HarrisonBTIG

BTIG

―

Hold

―

Downgraded

06/17/24

Aerovate Therapeutics downgraded to Neutral from Buy at BTIGAerovate Therapeutics downgraded to Neutral from Buy at BTIG

Tiago FauthWells Fargo

Wells Fargo

$70

Hold

915.97%

Upside

Downgraded

06/17/24

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alcon (NYSE: ALC), Aerovate Therapeutics (NASDAQ: AVTE) and Globus Medical (NYSE: GMED)

Dennis DingJefferies

Jefferies

$2,275→$70

Hold

915.97%

Upside

Downgraded

06/17/24

Aerovate Therapeutics downgraded to Hold from Buy at JefferiesAerovate Therapeutics downgraded to Hold from Buy at Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jade Biosciences

1 Month

xxx

Success Rate

0/2 ratings generated profit

Average Return

-57.20%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -57.20% per trade.

3 Months

xxx

Success Rate

0/2 ratings generated profit

Average Return

-56.40%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -56.40% per trade.

1 Year

Laura ChicoWedbush

Success Rate

0/2 ratings generated profit

Average Return

-55.95%

reiterated a buy rating 25 days ago

Copying Laura Chico's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -55.95% per trade.

2 Years

xxx

Success Rate

0/2 ratings generated profit

Average Return

-56.15%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -56.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JBIO Analyst Recommendation Trends

Rating

May 24

Jun 24

Jul 24

Aug 24

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JBIO has received 4 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. JBIO average Analyst price target in the past 3 months is 17.00.

Each month's total comprises the sum of three months' worth of ratings.

JBIO Financial Forecast

JBIO Earnings Forecast

Next quarter’s earnings estimate for JBIO is -$6.03 with a range of -$14.35 to -$2.05. The previous quarter’s EPS was -$0.19. JBIO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year JBIO has Preformed in-line its overall industry.

JBIO Sales Forecast

Next quarter’s sales forecast for JBIO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. JBIO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year JBIO has Preformed in-line its overall industry.

JBIO Stock Forecast FAQ

What is JBIO’s average 12-month price target, according to analysts?

Based on analyst ratings, Jade Biosciences’s 12-month average price target is 17.00.

What is JBIO’s upside potential, based on the analysts’ average price target?

Jade Biosciences has 146.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JBIO a Buy, Sell or Hold?

Jade Biosciences has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Jade Biosciences’s price target?

The average price target for Jade Biosciences is 17.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $17.00. The average price target represents 146.73% Increase from the current price of $6.89.

What do analysts say about Jade Biosciences?

Jade Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of JBIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Jade Biosciences (JBIO) Stock Forecast & Price Target

JBIO Analyst Ratings

JBIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jade Biosciences

JBIO Analyst Recommendation Trends

JBIO Financial Forecast

JBIO Earnings Forecast

JBIO Sales Forecast

JBIO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts